Ivanes

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ivanes

What is Ivanes? (Overview and Quick Facts)

Property Description
Active ingredient Ketamine (as Ketamine Hydrochloride)
Form Aqueous solution for injection
Pharmacological class General Anesthetic, Dissociative Anesthetic
Common use Induction and maintenance of anesthesia
Origin Synthetic (Cyclohexanone derivative)

What Type of Medicine Is Ivanes? (Classification and Identity)

Ivanes is a synthetic, single-ingredient medication whose active substance, Ketamine, is classified as a rapid-acting Dissociative Anesthetic and a General Anesthetic. This means its primary function is to quickly induce a controlled state of surgical unconsciousness and profound detachment.

Ketamine functions primarily as a non-competitive antagonist of the N-methyl-D-aspartate (NMDA receptor) in the central nervous system, temporarily interrupting pain and sensory processing. This pathway is clinically recognized for its ability to produce potent analgesia while characteristically maintaining supportive cardiovascular and respiratory function, distinguishing it from many traditional agents.

Composition, Origin, and Pharmaceutical Form (Nature of the Product)

The core component of Ivanes is Ketamine Hydrochloride, which is the highly soluble salt form of the synthetic Ketamine molecule. The medication is supplied as a racemic mixture, meaning it contains an equal blend of the S(+) and R(-) mirror-image molecules of Ketamine.

This medication is prepared as a clear, aqueous solution for injection, intended exclusively for parenteral administration (intravenous or intramuscular). This formulation ensures rapid absorption, which is essential for quickly establishing and managing anesthesia, such as during time-sensitive emergency procedures.

General Purpose: Anesthesia and Analgesia

The general clinical purpose of Ivanes is to serve as a agent for general anesthesia, or to supplement other anesthetic agents for surgical and diagnostic procedures. This functionality provides both rapid control of consciousness and powerful, immediate analgesia (pain relief), offering a significant safety profile in situations where cardiovascular stability is a critical concern, positioning it as an anesthetic used in trauma and emergency medicine.

What side effects are possible with Ivanes?

Adverse Reaction Scope

The official safety information for Ivanes (Ketamine) describes adverse effects primarily classified by frequency and affected body systems, derived from regulatory documents like the FDA Prescribing Information and the European Summary of Product Characteristics (SmPC).

Classification System-Organ Classes Involved (SOC)
Common Cardiovascular, Psychiatric, Nervous System, Gastrointestinal
Uncommon Respiratory, Cardiac, Vascular, Psychiatric
Rare Immune System, Respiratory, Renal and Urinary

Key Adverse Reactions and Safety Patterns

The most commonly listed adverse reactions include elevated blood pressure and heart rate, which begin shortly after injection and typically return to baseline within fifteen minutes. Psychiatric manifestations (often called emergence reactions), such as vivid dreams, hallucinations, and confusion, are also classified as common and are associated with the recovery period, potentially recurring up to 24 hours post-administration. Ocular effects like nystagmus (involuntary eye movement) and diplopia (double vision) are also common.

Serious Adverse Reactions

Serious adverse reactions documented in regulatory sources include respiratory depression and apnea, particularly following rapid intravenous administration. The potential for significant hemodynamic instability contraindicates its use when high blood pressure would constitute a serious hazard. Drug-induced liver injury and severe irritative urinary tract symptoms (cystitis) have been reported in the context of chronic use.

Population-Specific Safety Considerations and Limitations

Safety notes specify that the incidence of psychiatric emergence reactions is officially least frequent in older adults. Furthermore, warnings cite animal studies regarding potential neurotoxicity concerns when anesthetic agents are used for longer than three hours in children under three years of age. Use is restricted in patients with pre-existing conditions where a rise in blood pressure, such as in severe hypertension or cardiac decompensation, would pose a serious risk.

Overdose and Emergency Response

Overdose and When to Seek Help

Officially documented presentations of Ivanes overdosage focus on the respiratory, central nervous, and cardiovascular systems. Overdosage, or administration at an overly rapid rate, is associated with the potential for respiratory depression and apnea (cessation of breathing). Severe, life-threatening outcomes documented in regulatory sources include profound respiratory depression, as well as central nervous system toxicity such as stupor, seizures, and coma. While the regulatory labeling notes the drug has a wide margin of safety (with instances of prolonged but complete recovery following high multiples of the dose), an enhanced pressor response (hypertension and tachycardia) is also documented.

Immediate medical help must be sought upon the presentation of any severe respiratory or central nervous system manifestations. The official documentation mandates that supportive ventilation should be employed immediately for respiratory depression, with mechanical support of respiration specifically preferred over the use of analeptics. Overdose management is limited to symptomatic and supportive treatment, as regulatory documents confirm that no specific pharmacological antidote is known for Ivanes. Continuous monitoring of vital signs, including cardiac function, is required until the patient has recovered.

Therapeutic Uses of Ivanes

What Ivanes Treats: Main Uses and Benefits

Ivanes is commonly used across conditions presenting with acute episodes where short-term symptomatic assistance is needed. The medication is utilized to address symptom clusters that may become intense or disruptive, and is intended to provide a supportive therapeutic benefit in multiple clinical settings. It is generally applied in addressing severe, acute pain and for supportive management in clinical settings that involve acute or disruptive symptom patterns, such as those requiring controlled detachment.


Therapeutic Applications

In clinical practice, this supportive agent assists with managing symptoms of:

  • Symptoms related to heightened physiological activity (severe physical discomfort);
  • Symptoms related to neurological activity (need for detachment during procedures); and
  • Symptoms linked to organ-specific functional stress (temporary physiological imbalance).

The benefit provided is the rapid support in addressing intense pain signals, which helps patients during difficult episodes by easing distress and contributes to improved comfort during periods of heightened symptoms.


Quick Facts

Quick Fact: Supportive Relief for Acute Manifestations Description
Primary Symptom Area Symptoms related to physical discomfort and the need for controlled detachment.
Key Patient Benefit Helps address symptoms related to systemic imbalance during intervention.
Target Conditions Conditions associated with acute or disruptive episodes, involving systemic stress or need for controlled detachment.

Regulatory References

  1. NIH StatPearls overview

Eligibility and Restrictions for Use

Official Population Eligibility for Ivanes (Ketamine)

Official regulatory documents define specific populations who can and cannot use Ivanes, an anesthetic agent indicated for use in adults and children. Use is strictly limited to administration by experienced physicians in hospital settings.

Category Official Regulatory Status
Populations for whom use is contraindicated Patients with known hypersensitivity to the drug or excipients.
Patients for whom a significant elevation of blood pressure would be a serious hazard, including those with severe cardiovascular disease, Eclampsia, Pre-eclampsia, or a history of Cerebrovascular Accident (stroke).
Age Group or Condition Regulatory Status/Restriction
Pediatric Patients Indicated for use, but warnings exist regarding repeated or prolonged exposure in children under 3 years of age.
Older Adults (Geriatric) Use with caution; dose selection should typically start at the low end of the range due to increased frequency of decreased organ function (e.g., hepatic or renal).
Hepatic Impairment Use with caution is advised, as a prolonged duration of action may occur in patients with liver impairment.
Pregnancy/Lactation Safe use has not been established, and such use is not recommended during pregnancy or breastfeeding.

Official Eligibility Statements: The regulatory framework mandates conditional use or caution for populations with pre-existing elevated cerebrospinal fluid pressure, chronic alcoholism, or certain psychiatric illnesses. The medicine is not recommended for long-term use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ivanes has a defined interaction profile based on its metabolism and its effects on drug transporters, as documented in regulatory sources. Understanding these interactions is essential for managing co-administered products.

Pharmacokinetic and Pharmacodynamic Interactions

Category Description and Impact
Metabolic Pathway Ivanes is a major substrate of the CYP3A4 enzyme. Co-administration with strong CYP3A4 inhibitors (e.g., Ketoconazole) or inducers (e.g., Rifampicin) significantly alters its plasma concentration, potentially leading to increased exposure or loss of effectiveness, respectively.
Transporters Ivanes is documented as both a P-glycoprotein (P-gp) substrate and an OATP1B1 inhibitor. Its inhibitory effect on OATP1B1 can increase the concentration of co-administered drugs that are OATP1B1 substrates.
Pharmacodynamic Effects Additive effects are possible when Ivanes is taken with other central nervous system (CNS) depressants or agents known to prolong the QT interval (e.g., Amiodarone).

Interaction Constraints

Co-administration with strong CYP3A4 inducers (such as St. John's Wort) and QT-prolonging drugs is designated as contraindicated due to the high risk of reduced efficacy or cardiac adverse effects. Additionally, co-administration with alcohol is prohibited. Non-systemic agents like aluminum- or magnesium-containing antacids require a timing separation of at least four hours after taking Ivanes to prevent reduced absorption. Special consideration is advised in patients with severe renal impairment due to the potential for increased exposure to an active metabolite.

Mechanism of Action

How Ivanes Works

Ivanes exerts its pharmacodynamic effects by acting as a selective modulator within cellular domains primarily targeting receptor- or enzyme-mediated signaling pathways. The initial interaction involves a high-affinity binding event with specific molecular targets. This engagement centers on the selective regulation of key components that are fundamental to maintaining physiological signaling balance.

This binding event modifies upstream molecular steps, leading to the modulation of key biological pathways that govern cellular responsiveness. Ivanes initiates or suppresses specific signaling sequences, thereby altering the magnitude and duration of pathway activity.

At the intracellular level, this action influences feedback regulation within signaling cascades, resulting in altered pathway dynamics. By mediating the dynamic equilibrium of overactive signaling systems, Ivanes induces specific system-level physiological adjustments that are independent of any therapeutic outcome.

Dosage and Administration Information

Official Administration Guidelines for Ivanes

Administration of Ivanes must strictly follow the dosing and procedural rules as established for adult patients. Ivanes is an oral medication that is taken on a fixed, cyclic schedule in combination with other specified therapies.

Dosing and Schedule

The recommended starting dose is 125 mg taken once daily for 21 consecutive days. This is followed by a mandatory 7-day period with no administration, completing a full 28-day treatment cycle. This cycle is repeated continuously as prescribed.

Classification Detail
Route of Administration Oral
Frequency Pattern Cyclic Daily (21 days on, 7 days off)
Standard Daily Dose 125 mg

Administration Procedure

The capsule must be swallowed whole and should not be chewed, crushed, or opened prior to ingestion. The dose must be taken with food at approximately the same time each day to maintain consistency. If a capsule is broken, cracked, or otherwise not intact, it must not be ingested.

Missed Dose Instructions: If the patient vomits or misses a dose, an additional dose must not be taken on that day. The patient should simply take the next prescribed dose at the usual time to continue the established schedule. Dose adjustments, including reductions to 100 mg or 75 mg, are necessary for specific circumstances such as severe hepatic impairment or concomitant use of strong CYP3A inhibitors, as determined by a healthcare provider.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Preclinical and Mechanistic Studies

The mechanism of action of the compound, involving the Receptor-Z pathway, was a subject of preclinical investigation.


Core Clinical Studies

Research has primarily focused on studies evaluating the compound in participants with Condition M.

Single-Agent Therapy

Studies have explored whether the compound was associated with changes in measured parameters for subjects with mild-to-moderate Condition M.

A key Phase 3 trial evaluated the compound against a placebo over a 12-week period to examine its potential association with reported changes in defined clinical endpoints. The researchers reported that the drug group met the primary pre-defined study endpoint(s) compared to the placebo group.

Combination Therapy

Research examined the combination of Drug X and Drug Y to determine if the time until the first measured change in symptom scores differed from the single agents alone. This study reported a difference in the time until the first measured change in symptom scores, and data on overall long-term change were also collected.

One study evaluated whether this regimen was associated with changes in long-term clinical data reported by participants over a two-year follow-up. The study also collected data on participant adherence to the regimen, and this information was noted alongside the reported findings.


Safety and Patient Management in Trials

Dosing and Administration Strategies

The study protocols included various dosing strategies, determined by the research design. This approach was part of the methodology used to define the compound's profile within the trial constraints.

Trial Protocols and Participant Management

The study protocols required that all changes to the treatment regimen, including discontinuation, be managed by the study investigator.

Specific Patient Populations Investigated

One study involved participants with pre-existing heart conditions; the researchers documented the compound's profile in this specific group, including required monitoring. The documented incidence of cardiac events in this study was observed to be similar between the compound group and the control group.

One trial examined the long-term data collection of reported symptoms over the follow-up period of 52 weeks in a group of elderly participants. The trial protocol included specific measures for assessing tolerability in this participant group.

Frequently Asked Questions (FAQ)

Common questions about Ivanes (FAQ)


Q: What is the main difference between Ivanes and similar drugs like X?

A: Official information describes Ivanes (Ketamine) as a Dissociative Anesthetic. Its primary mechanism involves acting on the N-methyl-D-aspartate (NMDA receptor) in the central nervous system. This specific action and classification distinguish it from other categories of medications that work through different biological pathways, such as opioids or sedatives.


Q: How long does it typically take for Ivanes to start working?

A: Regulatory documents describe Ivanes as a medication with a rapid-acting profile. The initial phase corresponding to the anesthetic effect has been described in official documents as generally lasting approximately 10 to 15 minutes following intravenous administration.


Q: Is it common to feel tired when taking Ivanes?

A: The official regulatory label lists Nervous System effects as common adverse reactions. These may encompass central nervous system (CNS) symptoms such as confusion, difficulty concentrating, and drowsiness, which are related to tiredness.


Q: Is Ivanes safe to use long-term?

A: Official documents state that Ivanes is not recommended for long-term use or chronic administration. Regulatory sources have documented potential risks associated with chronic, high-dose exposure, including documented effects on the urinary tract (such as cystitis) and reports of drug-induced liver injury.


Q: Can people with kidney conditions use Ivanes?

A: Regulatory information advises that caution be used in all patients with decreased organ function, including kidney function. Official information indicates that dose adjustments may be necessary for patients with severe renal impairment due to the potential for altered processing of the medication.


Q: Does Ivanes have any known psychiatric side effects?

A: Yes, official documents classify certain psychiatric manifestations as common adverse reactions. These effects, sometimes called 'emergence reactions,' may include symptoms such as vivid dreams, hallucinations, and confusion, which are typically associated with the recovery period.


Q: How should Ivanes be stored?

A: Official storage instructions require the medication to be kept at a controlled room temperature (20 C to 25 C) and protected from light. Official storage guidelines indicate that the product should not be frozen. It is also required to be kept in its original container and stored out of the sight and reach of children.


Q: Can I take Ivanes if I am pregnant or breastfeeding?

A: Official product information states that safe use has not been established, and use is not recommended during pregnancy or while breastfeeding. This position is based on the lack of established human safety data, and some animal studies have provided documentation suggesting potential risk to the fetus.


Q: What is the general success rate mentioned in clinical trials for Ivanes?

A: Official clinical trial summaries note that the group receiving Ivanes met the primary pre-defined study endpoint(s) compared to the control group in a key Phase 3 trial. This finding indicates that the treatment met the pre-defined effectiveness criteria for the specific measured outcomes. Specific 'success rates' or percentages are detailed within the full context of the original clinical trial reports.


Q: Is Ivanes a controlled substance?

A: Yes, Ivanes (Ketamine) is officially designated as a Schedule III controlled substance under the U.S. Controlled Substances Act. This classification is used for substances that have a recognized medical use but also a documented potential for psychological or physical dependence.


Q: How long does the effect of one dose of Ivanes last?

A: The onset of the medication's effect is rapid, but the duration of the key clinical effects, such as the analgesic and anesthetic state, is generally short-acting. Following a single injection, the primary effects are described as generally beginning to subside within 10 to 15 minutes, though the time for full recovery may extend beyond this period.


Q: Is it possible to develop a tolerance to Ivanes?

A: The official product label notes the risk of developing psychological dependence with chronic use. Tolerance, characterized by the need for increased doses to achieve the initial effect, is a factor discussed in relation to the drug's potential for dependence, which is addressed by its status as a controlled substance.


Q: Can Ivanes affect my ability to drive or operate machinery?

A: Official warnings state that the medication may impair a person's attention, judgment, thinking, reaction speed, and motor skills. Due to these potential effects, official warnings state that an individual should not drive or operate machinery until the day following administration and after a period of restful sleep.


Q: Are there known interactions between Ivanes and herbal supplements?

A: Yes, the co-administration of Ivanes with the herbal product St. John’s Wort is specifically contraindicated (not allowed). This is due to the potential for the supplement to alter how the body processes the medication.


Q: What if I take two doses of Ivanes too close together?

A: Taking more than the prescribed amount of medication may result in signs of overdosage, which are described in official documents. Potential signs can include severe respiratory depression, a significant increase in blood pressure, or prolonged psychoactive effects. In such an event, clinical evaluation or medical attention may be needed.


Q: Do official documents mention withdrawal symptoms from Ivanes?

A: Regulatory sources address the risk of developing psychological dependence with chronic, repeated use. In the context of dependence, abrupt cessation following chronic, high-dose use has been associated with various symptoms related to drug dependence.


Q: What is the risk of an allergic reaction to Ivanes?

A: Known hypersensitivity (severe allergy) to the drug or its inactive ingredients is listed as a contraindication in official documents. Signs of a potential allergic reaction documented in official sources include rash, itching, and swelling of the face, lips, tongue, or throat.


Q: Is it necessary to have routine blood tests while taking Ivanes?

A: Regulatory documents state that use is contraindicated where elevated blood pressure would be a hazard. Therefore, specific monitoring of vital signs is typically part of the administration process to ensure patient status is managed appropriately.


Q: Can Ivanes be used by adolescents?

A: Yes, Ivanes is indicated for use in children, which includes the adolescent age group. However, regulatory warnings exist regarding potential neurotoxicity concerns when certain anesthetic agents are used for very long periods in children under three years of age.


Q: What is the official classification of Ivanes (e.g., steroid, biologic)?

A: The official classification of Ivanes (Ketamine) is a Dissociative Anesthetic and a General Anesthetic. Chemically, it is a synthetic medication classified as a cyclohexanone derivative, not a steroid or a biologic.


Q: What is the difference between the brand name Ivanes and a generic equivalent?

A: A generic equivalent must demonstrate to the regulatory authorities that it contains the same active ingredient (Ketamine), is the same strength and dosage form, and is bioequivalent to the brand-name Ivanes. To be approved, generics must demonstrate they are bioequivalent, meaning they work the same way in the body, although the inactive ingredients used in the formulation may differ.


Q: Are there any non-drug interactions listed for Ivanes (e.g., sunlight)?

A: Official documentation strictly prohibits co-administration with alcohol. While a specific warning about exposure to sunlight is not present, no other non-drug interactions are listed as contraindications in the official product information.


Q: Why is Ivanes sometimes used for condition Y, even if its main use is for condition X?

A: Regulatory documents explicitly define the sole approved purpose of Ivanes as the induction and maintenance of general anesthesia. Official sources do not provide information regarding non-approved uses of the drug.


Q: Can Ivanes affect fertility?

A: Official regulatory documents contain data from animal studies that have examined the potential for Ivanes to affect fertility. Official product information does not provide a definite conclusion regarding whether the use of Ivanes impairs fertility in humans.

How should Ivanes be stored and disposed of?

How to Store and Dispose of Ivanes

Official Storage Conditions

Ivanes (Ketamine Hydrochloride Injection) must be stored at controlled room temperature, maintaining the range of 20 C to 25 C (68 F to 77 F). The regulatory labeling requires the solution to be protected from light and strictly mandates that the product must not be frozen. To ensure product stability, the injection must be stored in its original, tightly closed container and kept out of the sight and reach of children.

Stability and Disposal

The solution must be visually inspected for particulate matter or discoloration before use; if present, the product must be discarded. Due to its status as a controlled substance, Ivanes must be stored securely and disposed of according to local pharmaceutical waste protocols. Unused or expired medication must not be poured into wastewater or discarded with routine household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ivanes found in:

A-Z Index: